Treatment of metastatic colorectal cancer in mice with CoFactor® in combination with Uftoral® (UFT) as demonstrated by clinical data recently reported by ADVENTRX Pharmaceuticals, Inc. (Amex: ANX).
CoFactor® is a folate-based drug designed to improve the efficacy and safety of the anticancer agent 5-fluorouracil (5-FU) while UFT is an oral anticancer drug approved for use in Asia and Europe that delivers a combination of tegafur, a prodrug of 5-FU, and uracil.
According to Evan M. Levine, ADVENTRX Pharmaceuticals, Inc.’s CEO:
"These CoFactor/UFT results are further evidence of CoFactor's improved ability over leucovorin to potentiate the efficacy of fluoropyrimidines. Results from numerous preclinical studies with and without the addition of oxaliplatin, anti-VEGF or gemcitabine suggest that CoFactor is more effective than leucovorin at modulating 5-FU, thereby increasing inhibition of tumor growth in colorectal, gastric and pancreatic tumor models while demonstrating reduced toxicity."
These results were presented as an abstract entitled: "5,10 Methylenetetrahydrofolate (CoFactor) Enhances UFT Antitumor Activity Against Human Colorectal HT-29 Tumor Xenografts in Nude Mice", at a joint meeting of the 7th International Conference of Asian Clinical Oncology Society (ACOS) & the 9th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) held September 16, 2006 in Beijing, China.
Find more details of the study in the press release.
.jpg)
Comment Preview